Navigation Links
Rivaroxaban phase III pivotal data presented at EFORT annual meeting
Date:5/30/2008

Nice, France (May 30, 2008) Results from a pivotal Phase III clinical trial presented today demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in patients who underwent total knee replacement (TKR) surgery. The head-to-head study compared rivaroxaban with the U.S.-approved dosing regimen for enoxaparin, the current standard of care.

Data from the RECORD4 clinical trial were presented at the annual meeting of the European Federation of National Associations of Orthopaedics & Traumatology (EFORT). Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.

The RECORD4 data show that rivaroxaban (10mg once-daily) provided TKR surgery patients a statistically significant 31% relative risk reduction (RRR) in total venous thromboembolism (VTE) events defined in the study as the composite of all deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality compared to enoxaparin (30mg twice-daily) (6.9% and 10.1%, respectively, p =0.012). Rates of major bleeding, the main safety endpoint, were low in both treatment groups, yet numerically greater in rivaroxaban-treated patients. This difference was not statistically significant from the rate of major bleeding in enoxaparin-treated patients (0.7% and 0.3% respectively; p=0.110). RECORD4 is the third of three, direct, head-to-head comparisons within the RECORD program to demonstrate the superior efficacy of rivaroxaban over enoxaparin with a similar adverse event profile.

"The superior efficacy and similar adverse event profile of rivaroxaban demonstrated in RECORD4 are in line with the outstanding results of the earlier RECORD studies," said Dr. A.G.G. Turpie, Professor of Medicine, McMaster University, Canada and Principal Investigator for the RECORD program. "The success of this trial strengthens my belief that d
'/>"/>

Contact: Stephen Cooper
stephen.cooper@edelman.com
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. TAK-390MR Phase 3 data presented at Digestive Disease Week
2. Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome
3. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
4. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
5. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
6. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
7. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
8. Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
9. Wal-Mart Launches Phase Three of $4 Prescription Program
10. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
11. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 26, 2014 BioSkinLaser.Com, the leading ... most advanced and improved laser treatments for its customers. ... treatments like the lip enhancement treatment . It ... specific focus areas of each customer. , BioSkinLaser.Com has ... reduction NYC . The company cited that it created ...
(Date:10/25/2014)... October 25, 2014 Background: , In ... (CCAR). He is a pioneer in the field of establishing ... Connecticut's state treatment system and when he retired, he set ... while in public service. , 1. Where ... decisions concerning them? , 2. Can the recovery community ...
(Date:10/25/2014)... Everett, WA (PRWEB) October 25, 2014 ... their insulation has ‘gone bad’ need wonder no more. ... that homeowners should watch out for when it ... Bad insulation, according to the article released by Clean ... emphasize for homeowners that any insulation that has deteriorated, ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... virus that causes common cold sores -- herpes simplex -- ... Swedish researchers suggest. In fact, being a carrier of ... Alzheimer,s disease, the researchers found. "The identification of ... disorder is a breakthrough," said lead researcher Dr. Hugo Lovheim, ...
(Date:10/25/2014)... Randy Dotinga HealthDay ... As more genetic tests are developed that spot increased risks ... be more proactive about getting screened. But a new ... not change behavior: People who found out their genes doubled ... people with average risk to get screened. "It didn,t ...
Breaking Medicine News(10 mins):Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 2Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 3Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
... eating away from home,could put kids at higher risk for ... this month,s research journal "Obesity.", SDSU public health researcher ... of relatives, neighbors or friends once a week,or more is ... Youngsters who ate away from home often drank more sugar-sweetened,beverages ...
... Two scientists who helped explain how embryos develop and ... to receive the 2008 March of Dimes Prize in Developmental ... J. Tabin, PhD will share the 2008 March of Dimes ... of how hedgehog genes and their protein signals guide the ...
... extra iron for infants who don,t need it might delay ... supplement levels and could have huge implications for the baby ... of research show problems with lack of iron. For us ... unexpected," said Dr. Betsy Lozoff, University of Michigan research professor ...
... initiative, US and Canadian experts have developed a ... resources during times of pandemic outbreaks or other ... legally protecting clinicians who follow accepted protocols for ... during mass critical care events. The framework represents ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ("China ... Bulletin,Board: CSKI), a leading fully integrated pharmaceutical ... People,s Republic of China,("PRC"), today announced the ... for its diagnostic kits., Harbin First ...
... research suggests that high-risk women with breast cancer who do ... for developing a second breast cancer than previously thought. ... sentinel node biopsy be considered at the time of prophylactic ... findings? , The increased risk of developing breast cancer ...
Cached Medicine News:Health News:SDSU Study Reveals Eating at Friends and Family's Puts Kids at Higher Risk for Obesity 2Health News:March of Dimes awards $250,000 prize to leaders in understanding embryonic development 2Health News:Iron supplements might harm infants who have enough 2Health News:New disaster preparedness strategy announced 2Health News:New disaster preparedness strategy announced 3Health News:New disaster preparedness strategy announced 4Health News:China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic Inspection Device for Diagnostic Kits 2Health News:China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic Inspection Device for Diagnostic Kits 3Health News:Second breast cancer may be greater than thought for high-risk women without BRCA mutations 2
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Second quarter overview: , Revenues of $53.9 million, ... Diluted EPS of $0.24, up 33% over last year,s ... revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... BEIJING, Aug. 4, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... the first fiscal quarter ended June 30, 2011 ("1Q ... 2011. The Company,s senior management will host ...
... N.J., Aug. 4, 2011 Omthera Pharmaceuticals, Inc., ... that Christian S. Schade will join the Company ... President and Chief Financial Officer, beginning in early ... experience as a public company financial executive in ...
Cached Medicine Technology:China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2011 on August 16, 2011 2Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer 2Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer 3
... DePuy 1 Gentamicin Bone Cement, a ... in the international market for over a ... antibiotic into cement. The premixed powder helps ... 1 Gentamicin Bone Cement provides the same ...
... 35 years, Palacos Bone Cement ... the gold standard in cemented ... introduction of,the Optivac system in ... provided thousands of physicians the ...
... Scanning Laser Doppler Flowmetry System ... Perfusion, ,The Heidelberg Retina Flowmeter uniquely ... laser scanning and laser Doppler flowmetry, ... that provides non-invasive two-dimensional mapping of ...
... Dosposable Easy Insertion/Removal ,The Mackool ... reliable support to the lens capsule ... phacoemulsification regardless of zonular status. ... disposable iris retractors), and removal is ...
Medicine Products: